Advertisement
Advertisement
U.S. Markets open in 6 hrs 42 mins
Advertisement
Advertisement
Advertisement
Advertisement

STRATA Skin Sciences, Inc. (SSKN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.0700-0.0400 (-3.60%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.1100
Open1.1400
Bid0.8000 x 1300
Ask1.6000 x 800
Day's Range1.0400 - 1.1300
52 Week Range1.0300 - 1.9500
Volume14,373
Avg. Volume26,244
Market Cap36.77M
Beta (5Y Monthly)1.97
PE Ratio (TTM)N/A
EPS (TTM)-0.0680
Earnings DateMar 22, 2022 - Mar 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.30
  • GlobeNewswire

    STRATA Skin Sciences Names Michael E. Goodman as Head of International Sales

    HORSHAM, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that Michael E. Goodman has been named STRATA’s Head of International Sales. In this newly created role, Mr. Goodman will be a key member of STRATA's expanding global commercial leadership team, with oversight of the Company’s commercial and sa

  • Zacks

    Strata Skin Sciences, Inc. (SSKN) Reports Q1 Loss, Tops Revenue Estimates

    Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of -40% and 1.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    STRATA Skin Sciences Reports First Quarter 2022 Financial Results

    HORSHAM, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the first quarter ended March 31, 2022. Recent Highlights Revenue in the first quarter 2022 of $7.0, a 21% increase over the first quarter of 2021Cash, cash equivalents and restricted cash at March 31, 2022 were $10.9 mill

Advertisement
Advertisement